US EditionHiv: Who Can Afford the Revolutionary New Treatment?
13 Articles
13 Articles
Europe authorises the marketing of lenacapavir, a preventive treatment against the AIDS virus, but its price, 28,000 dollars per patient per year, creates polemics.
The European Commission has approved the marketing authorisation of a twice-yearly injectable HIV drug from the US company Gilead Sciences. It was developed by Czech virologist and biochemist Tomáš Cihlář. The approval follows a recommendation from the European Medicines Agency (EMA) last month that the drug is highly effective in preventing HIV.
The approval of lenacapavir sesseral rejuvenates expectations in the fight against HIV. The injection showed almost 100% effectiveness in preventing infection by the AIDS virus.
On August 26, the European Commission (EC) granted a marketing authorization for the HIV vaccine Lenacapavir from Gilead (USA), allowing it to be present in 27 EU countries, as well as Norway, Iceland and Liechtenstein. However, the cost of the injection is sky-high.
Major development in the field of HIV prevention: the European Commission has approved lenacapavir, the first and only pre-exposure prophylaxis (PrEP) option that is administered twice a year…More...
The European Commission granted marketing authorisations for semi-injection of Gilead Sciences to prevent HIV infection, announced to the company this afternoon (26). Read more (08/26/2025)
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
